- Home
- SLN vs PFD Comparison
SLN vs PFD Comparison
Compare SLN & PFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- PFD
- Stock Information
- Founded
- SLN 1994
- PFD 1990
- Country
- SLN United Kingdom
- PFD United States
- Employees
- SLN N/A
- PFD N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- PFD Investment Managers
- Sector
- SLN Health Care
- PFD Finance
- Exchange
- SLN Nasdaq
- PFD Nasdaq
- Market Cap
- SLN 165.3M
- PFD 144.5M
- IPO Year
- SLN N/A
- PFD N/A
- Fundamental
- Price
- SLN $5.41
- PFD $11.07
- Analyst Decision
- SLN Buy
- PFD
- Analyst Count
- SLN 5
- PFD 0
- Target Price
- SLN $32.60
- PFD N/A
- AVG Volume (30 Days)
- SLN 170.8K
- PFD 33.2K
- Earning Date
- SLN 05-08-2025
- PFD 01-01-0001
- Dividend Yield
- SLN N/A
- PFD 6.30%
- EPS Growth
- SLN N/A
- PFD N/A
- EPS
- SLN N/A
- PFD N/A
- Revenue
- SLN $27,701,000.00
- PFD N/A
- Revenue This Year
- SLN N/A
- PFD N/A
- Revenue Next Year
- SLN N/A
- PFD N/A
- P/E Ratio
- SLN N/A
- PFD N/A
- Revenue Growth
- SLN N/A
- PFD N/A
- 52 Week Low
- SLN $1.97
- PFD $8.53
- 52 Week High
- SLN $22.47
- PFD $11.18
- Technical
- Relative Strength Index (RSI)
- SLN 64.31
- PFD 54.57
- Support Level
- SLN $4.69
- PFD $10.97
- Resistance Level
- SLN $6.35
- PFD $11.10
- Average True Range (ATR)
- SLN 0.53
- PFD 0.10
- MACD
- SLN 0.08
- PFD -0.01
- Stochastic Oscillator
- SLN 62.25
- PFD 58.22
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.